PDS Biotechnology (NASDAQ:PDSB – Get Free Report) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.
Several other research firms also recently issued reports on PDSB. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research note on Thursday, October 24th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $14.25.
Read Our Latest Research Report on PDS Biotechnology
PDS Biotechnology Trading Up 0.3 %
PDS Biotechnology (NASDAQ:PDSB – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter last year, the company earned ($0.37) EPS. On average, research analysts anticipate that PDS Biotechnology will post -1.24 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. Tempus Wealth Planning LLC bought a new position in PDS Biotechnology in the 2nd quarter valued at about $55,000. Ground Swell Capital LLC bought a new position in shares of PDS Biotechnology during the second quarter valued at about $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of PDS Biotechnology in the 2nd quarter worth approximately $115,000. Squarepoint Ops LLC bought a new position in PDS Biotechnology in the 2nd quarter valued at $120,000. Finally, Cubist Systematic Strategies LLC bought a new stake in PDS Biotechnology in the second quarter worth about $146,000. Institutional investors and hedge funds own 26.84% of the company’s stock.
About PDS Biotechnology
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
See Also
- Five stocks we like better than PDS Biotechnology
- 5 discounted opportunities for dividend growth investors
- Battle of the Retailers: Who Comes Out on Top?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Insider Trading – What You Need to Know
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for PDS Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDS Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.